On November 10, 2020 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, reported it will host a conference call and webcast to provide a business update on Tuesday, November 17, 2020 at 4:30 p.m. EST (Press release, Cue Biopharma, NOV 10, 2020, View Source [SID1234608291]). Live and archived versions of the event can be accessed via the Company’s website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Members of the Cue Biopharma executive management team will provide a clinical update including details pertaining to patients from cohorts 4, 5 and 6 in the Company’s ongoing Phase 1 monotherapy dose escalation clinical trial of CUE-101 for the treatment of HPV16-driven recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Management will also provide an update on the Company’s technology platforms and pipeline progress, as well as updates on its strategic objectives and anticipated milestones.
Tuesday, November 17 at 4:30 p.m. EST
Investors:
International:
Conference ID:
Webcast: 877-407-9208
201-493-6784
13712195
View Source